RYEQO PROMOTIONAL MATERIALS

The global ad campaign based on the ballerina concept – for use in press/print or any static medium

The ballerina represents the brand Ryeqo – promising bold, life-transforming performance

The headline, visual and endline (Her life is our performance) should be used together as shown were possible. Lead with Fabiana

Moving imagery versions of the global concept for use in digital items

The moving imagery provides another level of confidence, bringing the campaign to life

There are 6s and 16s versions of each of the three ballerinas available – each uses ‘Ryeqo music’ too

RYEQO core sales aid with the approved narrative and story flow – now updated with the full 1-year data

To provide you with the key customer sales material and now with the latest published data

Details the complete RYEQO sales story – the unmet need, the LIBERTY trial programme overview, efficacy and long-term improvement in QoL for patients with UF

A page-by-page guide on how to use the sales aid

How we talk around the data and anticipating any objections will be key to communicating a strong Ryeqo sales story

The User Guide can be printed or used as a pdf – providing full direction on how to use the sales aid

A simply key message summary piece that can be left with the customer

It is important that we use a consistent brand summary across all materials and markets

This piece is a simple 4-pager, with a cut-short front cover – once opened, all the key messages are visible alongside a relevant graphic icon

An extensive Mode of Action animation

This animation explains everything from the typical symptoms, how estrogen and progesterone levels influence fibroid growth and how Ryeqo works to stop this

Three edits are available: a longer one containing the entire story – and two shorter edits focusing more specifically on the Ryeqo mode of action. Full files available on request

Brand monograph containing all key epidemiological and clinical data

Provides extensive information about many aspects of the disease and the key clinical trials for Ryeqo. May be a mandatory item in some markets

Can be adapted and printed or used as a PDF

Product website containing key messages, SmPC and other useful resources

Many customers will go online and expect to see key information about Ryeqo

This is the central, regional  version that can be adapted locally if required. Contact the Global Team for local implementation

Series of training modules covering everything from the disease to Ryeqo data

It’s important we all understand these topics fully and communicate them consistently

Strictly for INTERNAL use only

A moving film covering all the key aspects of the fully published NEJM paper

This is a pivotal and very important published paper for Ryeqo

Can be shown to or shared with customers (there is no branding on this so can be viewed as educational)

Document containing frequently asked questions about Ryeqo

It is important we all know what questions our customers are likely to ask about Ryeqo and how we should all answer them consistently

PDF brochure for internal use only

An internal use only comparator piece that summarises the differences between Ryeqo SmPC and Yselty SmPC

To help you clearly differentiate Ryeqo from Yselty when creating external pieces and show they are not the same. Including, convenience and tablet formulation, use in special populations and bone mineral density

Highlights the exact wording from the SmPC to show the Ryeqo vs Yselty differences, and then explains what this means in everyday practice for both HCPs and their patients

An external leave-piece that summarises the three pillars that support the use of Ryeqo and the reasons why HCPs should use Ryeqo for their patients with UF

HCPs need to know simply and concisely the key reasons why they should use Ryeqo

Summarises the key data and unique selling points for Ryeqo into the three R’s: Real-Life; Robustness; Reassurance

An external detail aid that celebrates the 1-year anniversary of Ryeqo approval by the EMA

To maintain post-launch momentum for Ryeqo and provide another touch-point with customers. To keep Ryeqo top of their mind and continue to raise awareness

A detail aid that summarises our brand story: the big unmet need and why a new level of Rx performance was needed, the Ryeqo efficacy and safety publication summary and the benefits it brings to patients

Showcases the 5 patient archetypes for RYEQO. Gives patient demographic, treatment history and patient journey background. Also provides patient quote about what she needs from treatment – which matches what RYEQO offers

To present clear picture in the mind of customers of who the RYEQO patients are. To help prevent RYEQO being niched purely as a treatment in patients with severe UF or those just with heavy bleeding. Raises awareness of other patient types and symptoms

5 clear, diverse patient archetypes that clearly show why RYEQO is a suitable treatment in each scenario

Ryeqo® IMAGE BANK

To ensure that all launch markets use only approved images and icons in their customer materials. This will enable us to present a consistent approach across all markets and streamline your local material development.

Image Bank document provides context and guidance – the Getty stock images are also saved here for immediate use.

An objection handler to help combat any concerns or questions surrounding any potential risk of blood clots with Reyqo, with customers

Because Ryeqo contains low-dose NETA (estradiol and norethisterone acetate) which is used in combined oral contraceptive pills, there have been some questions about whether this could potentially lead to the risk of blood clots observed with some contraceptive pills

This must only be used REACTIVELY – if and when there is any customer concern about this potential risk

Post Prescription leaflet for women prescribed Ryeqo

To support women when they start taking Ryeqo – how to take it, what to expect, how long before it starts to work and so on. By better supporting women taking Ryeqo, we are more likely to optimise their experience and outcome on our brand

The leaflet can only be given once a woman has been prescribed Ryeqo. In some countries, the brand logo/colourways can be used but you will need to check this within your specific market

Leave-piece summarising the 104 Week efficacy and safety data with RYEQO

To show that RYEQO sustains long-term reduction in menstrual blood loss, with a long-term safety profile that had no new signals and was similar to placebo

This leave piece can be given to your customers after you have detailed the CVA during your call